BackAN2 Therapeutics Overview

AN2 Therapeutics Current Cash

Latest current cash for ANTX: $53M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$53.49M
↑ 167.64% YoYΔ $33.50M vs prior year quarter

Peer average

Loading

AN2 Therapeutics Current Cash History

Loading

AN2 Therapeutics vs. peers: Current Cash Comparison

Loading

AN2 Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AN2 Therapeutics (ANTX) FAQ

As of the most recent data (March 2026), ANTX shows a current cash of $53M. That compares with $20M in the prior-year period — up 167.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ANTX's current cash is now $53M (was $20M) — a 167.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether AN2 Therapeutics is outperforming or lagging.

Tracking ANTX's current cash over time shows whether AN2 Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $53M That compares with $20M in the prior-year period — up 167.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has AN2 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $53M) with ownership activity and broader fundamentals.